These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
499 related articles for article (PubMed ID: 27816545)
1. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Wu T; Chen Z; To KKW; Fang X; Wang F; Cheng B; Fu L Biochem Pharmacol; 2017 Jan; 124():29-42. PubMed ID: 27816545 [TBL] [Abstract][Full Text] [Related]
2. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876 [TBL] [Abstract][Full Text] [Related]
3. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo. Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682 [TBL] [Abstract][Full Text] [Related]
4. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847 [TBL] [Abstract][Full Text] [Related]
5. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547 [TBL] [Abstract][Full Text] [Related]
6. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202. Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055 [TBL] [Abstract][Full Text] [Related]
7. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821 [TBL] [Abstract][Full Text] [Related]
8. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo. Chen Z; Chen Y; Xu M; Chen L; Zhang X; To KK; Zhao H; Wang F; Xia Z; Chen X; Fu L Mol Cancer Ther; 2016 Aug; 15(8):1845-58. PubMed ID: 27196753 [TBL] [Abstract][Full Text] [Related]
9. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter. Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534 [TBL] [Abstract][Full Text] [Related]
10. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia. To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183 [TBL] [Abstract][Full Text] [Related]
11. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658 [TBL] [Abstract][Full Text] [Related]
12. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells. Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704 [TBL] [Abstract][Full Text] [Related]
13. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo. Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405 [TBL] [Abstract][Full Text] [Related]
14. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420 [TBL] [Abstract][Full Text] [Related]
15. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells. Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527 [TBL] [Abstract][Full Text] [Related]
16. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo. Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496 [TBL] [Abstract][Full Text] [Related]
17. Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. Zhang YK; Zhang GN; Wang YJ; Patel BA; Talele TT; Yang DH; Chen ZS Sci Rep; 2016 May; 6():25694. PubMed ID: 27157787 [TBL] [Abstract][Full Text] [Related]
18. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011 [TBL] [Abstract][Full Text] [Related]
19. CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. Tang SJ; Chen LK; Wang F; Zhang YK; Huang ZC; To KK; Wang XK; Talele TT; Chen ZS; Chen WQ; Fu LW Biochem Pharmacol; 2014 Sep; 91(2):144-56. PubMed ID: 25058526 [TBL] [Abstract][Full Text] [Related]
20. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells. Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]